Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.32
Oct 21 • 10:17 AM ET Dollar change-0.07 Percentage change(-5.04%)
Index
RUT
Market Cap
35.17M
Enterprise Value
29.97M
Income
-51.97M
Sales
61.19M
Book/sh
0.75
Cash/sh
2.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
223
IPO
Jun 30, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
0.57
P/B
1.76
P/C
0.54
P/FCF
-
EV/EBITDA
-
EV/Sales
0.49
Quick Ratio
6.87
Current Ratio
8.04
Debt/Eq
2.98
LT Debt/Eq
2.96
Option/Short
Yes / Yes
EPS (ttm)
-1.97
EPS next Y
-1.93
EPS next Q
-0.50
EPS this Y
1.38%
EPS next Y
3.89%
EPS next 5Y
5.35%
EPS past 3/5Y
-0.43% -22.44%
Sales past 3/5Y
36.11% 56.40%
EPS Y/Y TTM
6.12%
Sales Y/Y TTM
11.96%
EPS Q/Q
6.30%
Sales Q/Q
15.57%
Insider Own
39.19%
Insider Trans
0.24%
Inst Own
31.47%
Inst Trans
2.90%
ROA
-49.06%
ROE
-133.44%
ROIC
-65.81%
Gross Margin
85.62%
Oper. Margin
-79.49%
Profit Margin
-84.93%
SMA20
-23.08%
SMA50
-46.39%
SMA200
-75.98%
Trades
Shs Outstand
26.64M
Shs Float
16.20M
52W High
11.30 -88.32%
52W Low
1.25 5.18%
Volatility
8.08% 11.74%
ATR (14)
0.18
RSI (14)
26.49
Beta
0.78
Rel Volume
0.10
Avg Volume
933.50K
Volume
15,569
Perf Week
-1.49%
Perf Month
-54.33%
Perf Quarter
-73.01%
Perf Half Y
-83.46%
Perf YTD
-81.41%
Perf Year
-86.89%
Perf 3Y
-89.78%
Perf 5Y
-91.57%
Perf 10Y
-
Prev Close
1.39
Price
1.32
Change %
-5.04%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binkowski BrentCHIEF OPERATING OFFICERAug 13 '26Buy2.9126,22376,43256,514Aug 13 08:18 PM
Binkowski BrentCHIEF OPERATING OFFICERAug 12 '26Sale2.551,3093,33830,291Aug 13 04:26 PM
Adamson Philip B.Chief Medical OfficerMar 02 '26Sale7.901,2629,97361,578Mar 16 04:16 PM
Hykes KevinPRES & CEOMar 02 '26Sale7.907,76361,349284,237Mar 03 06:03 PM
VERRASTRO PAULCHIEF MKTG & STRAT OFFICERMar 02 '26Sale7.901,28410,14660,551Mar 03 06:03 PM
OASHEIM JAREDCHIEF FINANCIAL OFFICERMar 02 '26Sale7.901,74413,78196,703Mar 03 06:02 PM
John Robert AllenChief Revenue OfficerMar 02 '26Sale7.903,96431,32686,036Mar 03 06:01 PM
Jain Mudit K.DirectorFeb 20 '26Buy6.3646,800297,592980,183Feb 23 06:00 AM
Jain Mudit K.DirectorFeb 18 '26Buy4.646002,7855,650Feb 18 05:22 PM
JOHNSON & JOHNSON10% OwnerNov 26 '25Sale10.036,33763,5604,040,861Dec 01 04:07 PM
JOHNSON & JOHNSON10% OwnerNov 24 '25Sale10.062,20022,1324,047,198Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 21 '25Sale10.005005,0004,049,398Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 12 '25Sale10.001,00010,0004,049,898Nov 14 03:07 PM
JOHNSON & JOHNSON10% OwnerNov 06 '25Sale10.2152,332534,3104,051,098Nov 10 03:28 PM
JOHNSON & JOHNSON10% OwnerNov 07 '25Sale10.002002,0004,050,898Nov 10 03:28 PM
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.
PresidentMr. Kevin Hykes
M.Sc.Dr. Philip B. Adamson M.D.